Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04822077Not ApplicableRecruiting

Study on Proton Radiotherapy of Thymic Malignancies

Role: lead

NCT01920789Not ApplicableUnknown

Stereotactic Precision And Conventional Radiotherapy Evaluation

Role: lead

NCT01664663Phase 2Terminated

Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy

Role: lead

All 3 trials loaded